Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

NCT00431067 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00431067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
Not reported
Enrollment
41 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms